Intelligent temperature control health care patch and preparation method thereof

Abstract

The invention discloses an intelligent temperature control health care patch and a preparation method thereof, and belongs to the technical field of medical instruments. The health care patch comprises a surface layer (a CO2 laser drilling PET film and a fluorosilane coating), a temperature control layer (paraffin / mesoporous silica composite phase change material), a medicine layer (wormwood essential oil-paraffin / sodium alginate microcapsules) and a bonding layer (silicone adhesive / hydrogenated castor oil). Ventilation and sweat prevention are achieved through the laser micropores and the hydrophobic coating, the phase change material composite system provides + / -1.4 DEG C temperature control precision, and the 48-hour medicine volatilization loss rate is only 3.2%. The preparation method adopts vacuum impregnation, low-temperature crosslinking and gradient curing processes, and interlayer bubble-free combination and efficient production are realized. The product has thermal therapy accuracy, medicine long-acting slow release property and skin adaptability, and is suitable for the field of chronic pain and joint nursing.

Description

Technical Field

[0001] The present invention relates to the technical field of medical devices, and in particular to an intelligent temperature-control health care patch and a preparation method thereof. Background Art

[0002] In recent years, with the improvement of living standards, many people are keen on aerobic exercise and fitness. However, due to incorrect exercise methods, some damage will be caused to the body during exercise. Soft tissue injuries are common and frequently occurring diseases in traumatology, with the ankle joint having the highest incidence rate among joint sprains. Early and effective protection and treatment can avoid ankle instability and persistent pain in the later stages. Effective treatment and care of acute ankle sprains in athletes are of great significance in the prevention and treatment of sports injuries. Sports contusion health patches can not only release and penetrate the skin to achieve local therapeutic effects, but also enter the systemic circulation through the skin via capillaries to exert systemic therapeutic effects.

[0003] Traditional health care patches mainly achieve physical therapy functions through hot compresses or transdermal absorption of drugs, but there are the following technical bottlenecks: Insufficient temperature control accuracy: Traditional heating patches mostly use iron powder oxidation to release heat, which has large temperature fluctuations (±5°C), can easily burn the skin, and the heat release rate cannot be adjusted as needed; phase change materials are prone to leakage when directly encapsulated and have poor long-term stability. Low drug release efficiency: Conventional drug carriers have weak adsorption capacity for essential oil components, volatilize and lose at room temperature, and lack temperature responsiveness, making it impossible to achieve body temperature-triggered controlled release. Poor attachment comfort: Ordinary adhesive layers are prone to residue and high sensitization rates, while silicone materials are not flexible enough and are prone to debonding during human activities. Manufacturing process defects: The traditional multi-layer composite process uses solvent-based adhesives, which can easily lead to degradation of the active ingredients in the drug layer, and improper hot pressing parameters can destroy the microstructure.

[0004] In response to the above problems, there is an urgent need to develop smart health patches that have precise temperature control, targeted drug release, high biocompatibility and process adaptability to meet the needs of personalized physical therapy. Summary of the Invention

[0005] The purpose of the present invention is to provide an intelligent temperature-controlled health care patch and a preparation method thereof, which solves the problems of existing health care patches such as drastic temperature fluctuations, poor drug penetration efficiency and poor attachment comfort.

[0006] The present invention achieves the above-mentioned purpose through the following technical solutions:

[0007] The intelligent temperature control health care patch is characterized by:

[0008] A surface layer, wherein the surface layer is prepared by punching holes in a medical PET film using a CO2 laser;

[0009] A temperature control layer attached to the surface layer, the temperature control layer is a phase change energy storage material composite system, the phase change energy storage material composite system is prepared by melting paraffin to 60°C, vacuum impregnating it into the pores of mesoporous silica under -0.1 MPa conditions, adding magnesium stearate and mixing evenly, and hot pressing at 50°C and 5 MPa conditions to form a sheet with a thickness of 0.5 mm;

[0010] A drug layer is attached to the surface of the temperature control layer, wherein the drug layer is prepared by mixing wormwood essential oil with molten paraffin, injecting it into a 2.5% sodium alginate solution, cross-linking it with 2% CaCl2 for 30 minutes, vacuum drying it at 45°C, and sieving 80-120 μm microcapsules;

[0011] and an adhesive layer adhered to the surface of the drug layer, wherein the adhesive layer is prepared by stirring silicone glue and hydrogenated castor oil in a blender for 30 minutes, coating the mixture on a PET release film, and curing the mixture at 80° C. for 20 minutes.

[0012] According to a preferred embodiment of the present invention, the wavelength of the CO2 laser is 10.6 μm, the power is 30 W, the aperture of the holes punched on the medical PET film is 20 μm, and the hole density is 300 holes / cm 2 ; Punching speed 500 holes / second.

[0013] According to a preferred embodiment of the present invention, the CO2 laser is a molecular laser. The primary substance is CO2 molecules, which can exhibit various energy states depending on their vibration and rotational patterns. The mixed gas in the CO2 forms a plasma, a low-pressure gas created by the release of electrons.

[0014] According to a preferred embodiment of the present invention, the CO2 laser is purchased from Dongguan Sprite Laser Technology Co., Ltd.

[0015] According to a preferred embodiment of the present invention, the raw material for preparing the medical PET film is polyethylene terephthalate (PET) particles.

[0016] According to a preferred embodiment of the present invention, the thickness of the medical PET film is 0.05 mm, and the tensile strength is ≥120 MPa.

[0017] According to a preferred embodiment of the present invention, the medical PET film is purchased from Jiangsu Shuangxing Color Plastic New Materials Co., Ltd.

[0018] According to a preferred embodiment of the present invention, the surface layer is sprayed with a fluorosilane coating, the thickness of the fluorosilane coating is 50 nm, and the contact angle is ≥110°.

[0019] In the present invention, the surface is sprayed with a fluorosilane coating to prevent external liquid from penetrating while allowing water vapor to pass through (moisture permeable but liquid-impermeable); the laser microporous structure reduces heat accumulation and avoids local overheating.

[0020] According to a preferred embodiment of the present invention, the paraffin wax is purchased from China Petrochemical Corporation.

[0021] According to a preferred embodiment of the present invention, the pore size of the mesoporous silica is in the range of 2-50 nm.

[0022] According to a preferred embodiment of the present invention, the mesoporous silica has a high specific surface area of 500-1500m 2 / g, high mechanical strength and thermal stability, controllable synthesis, adjustable pore size and specific surface area, etc.

[0023] According to a preferred embodiment of the present invention, the application scope of the mesoporous silica includes catalysis, adsorption, separation, and drug delivery.

[0024] According to a preferred embodiment of the present invention, the mesoporous silica is selected from at least one of MCM-41 and SBA-15. According to a preferred embodiment of the present invention, the mesoporous silica is prepared by at least one of a template method, a deposition method, and a hydrothermal method.

[0025] According to a preferred embodiment of the present invention, the mesoporous silica is purchased from Zhejiang Yamei Nano Technology Co., Ltd.

[0026] According to a preferred embodiment of the present invention, the magnesium stearate chemical formula is C 36 H 70 MgO4, molecular weight is 591.24.

[0027] According to a preferred embodiment of the present invention, the magnesium stearate is a white, non-gritty fine powder that has a greasy feel when in contact with the skin.

[0028] According to a preferred embodiment of the present invention, the magnesium stearate is insoluble in water, ethanol or ether, and is mainly used as a lubricant, anti-adhesive agent and glidant.

[0029] According to a preferred embodiment of the present invention, the magnesium stearate can be used as a filter aid, a clarifying agent, a dripping agent, and a suspending agent and a thickening agent for liquid preparations.

[0030] According to a preferred embodiment of the present invention, the magnesium stearate is purchased from Shandong Fengtai Biotechnology Co., Ltd.

[0031] According to a preferred embodiment of the present invention, the principle of hot pressing to form a sheet with a thickness of 0.5 mm is to achieve material densification and shaping through the synergistic effect of temperature and pressure.

[0032] According to a preferred embodiment of the present invention, the process flow of hot pressing the phase change energy storage material composite system into a sheet with a thickness of 0.5 mm is as follows: 1) Vacuum impregnation: After the paraffin is melted (60°C), mesoporous silica is impregnated under a vacuum degree of -0.1MPa. The impregnation efficiency is more than 95%, and the pore filling rate is ≥90%. 2) Additive dispersion: 5-10wt% magnesium stearate is added and uniformly dispersed by mechanical stirring (speed 300rpm, time 15min) to inhibit material leakage during subsequent hot pressing. 3) Hot pressing molding: 45-50°C / normal pressure / 5min preheating to eliminate the internal stress of the preform, 50°C / 5MPa / 20min main pressure to achieve complete filling of the nanopores. Maintain the pressure and cool to 30°C, and the molding thickness is 0.5mm±0.02mm.

[0033] According to a preferred embodiment of the present invention, the phase change energy storage material complex further comprises a temperature-responsive sustained-release matrix, which is composed of 15-20% poly N-isopropylacrylamide (PNIPAM), 30-40% carboxymethyl chitosan (CMCS) and 10-15% glutaraldehyde glycidol.

[0034] According to a preferred embodiment of the present invention, the temperature-responsive sustained-release matrix is prepared by mixing PNIPAM and CMCS in a mass ratio of 1:2, adding 0.5% glutaraldehyde glycidol for cross-linking, and curing at 50°C for 2 hours to form a porous network with pore sizes of 10-50 μm. The PNIPAM / CMCS gel shrinks by >40% at temperatures above 32°C, automatically limiting excessive drug release.

[0035] According to a preferred embodiment of the present invention, the drug layer further comprises a fast permeation layer, and the fast permeation layer is composed of 12% azone, 8% menthol and 21.5% ferulic acid.

[0036] According to a preferred embodiment of the present invention, the method for preparing the rapid permeation layer comprises mixing azone with melted lanolin (60°C) at a ratio of 1:1, adding Chuanxiong extract (supercritical CO2 extraction), and grinding with three rollers to a fineness of ≤10 μm; coating on 80 g / m 2 Non-woven fabric, dried at 60℃, thickness 0.3mm.

[0037] According to a preferred embodiment of the present invention, the drug layer further comprises an active co-crystal layer, namely, notoginseng saponin-Achyranthes bidentata total flavonoids co-crystal (solubility 28.5 mg / mL).

[0038] According to a preferred embodiment of the present invention, the preparation method of the active eutectic layer includes: mixing notoginseng saponins and total flavonoids of Achyranthes bidentata in a molar ratio of 1:1.5, adding a saturated solution of β-cyclodextrin, and crystallizing by rotary evaporation at 45°C; after freeze-drying, crushing to 200 mesh, mixing with hydroxypropyl methylcellulose (HPMC) and coating.

[0039] According to a preferred embodiment of the present invention, the preparation method of the drug layer is to stack the fast permeation layer and the eutectic layer in sequence, and hot-press them at 60°C and 0.5MPa pressure to obtain an interlayer bonding force of ≥8N / cm.

[0040] The wormwood essential oil is extracted from the wormwood plant and is generally applied externally on the skin to help kill bacteria and reduce inflammation, and improve local skin redness, itching and other problems caused by these factors.

[0041] The mugwort essential oil of the present invention can promote the discharge of cold air in the body through abdominal massage to relieve pain and alleviate menstrual pain caused by uterine cold.

[0042] The wormwood essential oil of the present invention has an improving effect on joint pain and swelling caused by severe dampness and cold in the body.

[0043] According to a preferred embodiment of the present invention, the mugwort essential oil is purchased from Shanghai Yuanye Biotechnology Co., Ltd.

[0044] According to a preferred embodiment of the present invention, the paraffin wax is a hydrocarbon mixture extracted from certain distillates of petroleum, shale oil or other asphalt mineral oils.

[0045] According to a preferred embodiment of the present invention, the paraffin wax, also known as crystalline wax, is a white, odorless waxy solid that melts at 47-64°C and has a density of about 0.9 g / cm 3 It is soluble in non-polar solvents such as gasoline, carbon disulfide, xylene, ether, benzene, chloroform, carbon tetrachloride, and naphtha, but insoluble in polar solvents such as water and methanol.

[0046] According to a preferred embodiment of the present invention, the paraffin wax is purchased from Fushun Yupeng Wax Industry Co., Ltd.

[0047] According to a preferred embodiment of the present invention, the sodium alginate solution is purchased from Shandong Haoyang Seaweed Industry Co., Ltd.

[0048] According to a preferred embodiment of the present invention, the CaCl2 Shandong Xinsheng Chemical Co., Ltd.

[0049] According to a preferred embodiment of the present invention, the drug loading capacity of the microcapsule is 8 mg / cm 2 .

[0050] The vacuum drying at 45° C. in the present invention can effectively balance the water evaporation rate and the stability of heat-sensitive components (such as mugwort essential oil), thereby avoiding microcapsule rupture or volatile matter loss caused by high temperature.

[0051] In the present invention, the low-temperature drying at 45° C. is adapted to the gel network formed by the 2% CaCl2 cross-linking in the early stage, thereby reducing the structural deformation caused by drying shrinkage.

[0052] In the present invention, vacuum drying at 45° C. combined with a sieving process (80-120 μm) can maintain the uniformity of the microcapsule morphology and avoid the particle size distribution deviation caused by high temperature (such as excessive shrinkage of sodium alginate segments at high temperature causing microcapsule adhesion).

[0053] According to a preferred embodiment of the present invention, the silicone adhesive is purchased from Hangzhou Zhijiang Organic Silicon Chemical Co., Ltd.

[0054] According to a preferred embodiment of the present invention, the hydrogenated castor oil is purchased from Inner Mongolia Weiyu Biotechnology Co., Ltd.

[0055] According to a preferred embodiment of the present invention, the PET release film is also called a PET silicone oil film, and a layer of silicone oil is coated on the surface of the PET film to reduce the adhesion of the PET film surface.

[0056] According to a preferred embodiment of the present invention, the PET release film is purchased from Jiangsu Sidike New Material Technology Co., Ltd.

[0057] According to a preferred embodiment of the present invention, the stirring conditions in the stirrer are: vacuum degree -0.08 MPa, rotation speed 200 rpm.

[0058] The present invention also provides a method for preparing an intelligent temperature-controlled health care patch, comprising the following steps:

[0059] S1, pre-combining the temperature control layer and the drug layer: aligning the temperature control layer and the drug layer and then hot pressing to ensure that there are no bubbles in the temperature control layer and the drug layer;

[0060] S2, surface lamination: apply medical-grade UV adhesive on the upper surface of the temperature control layer, cover with PET film, and UV cure;

[0061] S3, adhesive layer lamination: remove the silicone release film, place the adhesive surface on the bottom of the drug layer, and roll to remove air bubbles;

[0062] S4, die-cutting: Use a circular die-cutting machine to cut into a standard size of 10 cm × 14 cm, with edge chamfer R = 1 mm.

[0063] According to a preferred embodiment of the present invention, the medical-grade UV glue is purchased from Dymax.

[0064] According to a preferred embodiment of the present invention, the circular die cutting machine is purchased from Nishimura.

[0065] According to a preferred embodiment of the present invention, in S1, the hot pressing conditions are: hot pressing at 60° C. and 0.3 MPa for 30 seconds.

[0066] According to a preferred embodiment of the present invention, in S2, the thickness of the UV glue is 10 μm, the thickness of the UV curing is 365 nm, and the density is 10 mW / cm 2 , time is 30 seconds.

[0067] According to a preferred embodiment of the present invention, in S3, the roller pressing pressure is 0.1 MPa and the speed is 5 m / min.

[0068] The beneficial effects of the present invention are:

[0069] 1. Multi-stage temperature control and long-term sustained release synergy

[0070] The temperature control layer achieves precise temperature control through a phase change material composite system, and works synergistically with the sustained-release function of the drug layer to dynamically adjust the drug release rate when triggered by human body temperature to match the needs of thermal therapy.

[0071] 2. Optimization of air permeability and bonding performance

[0072] The surface layer uses a microporous structure and hydrophobic coating design to improve breathability and prevent sweat infiltration, combined with a high-adhesion adhesive layer to achieve long-term skin fit, balancing comfort and stability.

[0073] 3. Improved drug loading efficiency of microcapsules

[0074] By optimizing the microcapsule preparation process, the drug loading and retention rate are significantly improved, breaking through the limitations of traditional patches with low drug loading density and high volatility.

[0075] 4. Adaptability to efficient production processes

[0076] The technology utilizes a synergistic combination of low-temperature hot pressing, vacuum drying, and light-curing processes to achieve high-precision interlayer bonding and rapid production, improving product consistency and manufacturing efficiency. Through multi-dimensional innovations in materials, structure, and process, this technology comprehensively enhances the temperature control accuracy, drug release efficacy, wearing comfort, and production controllability of the health patch, making it suitable for chronic pain management and thermal therapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0077] Figure 1 This is the structural diagram of the smart temperature control health patch. DETAILED DESCRIPTION

[0078] The present application is described in further detail below in conjunction with the accompanying drawings. It is necessary to point out that the following specific implementation methods are only used to further illustrate the present application and cannot be understood as limiting the scope of protection of the present application. Technicians in this field can make some non-essential improvements and adjustments to the present application based on the above application content.

[0079] 1. Implementation

[0080] Preparation method of intelligent temperature control health care patch:

[0081] 1. Raw material preparation and pretreatment

[0082] 1) Surface material processing

[0083] A CO2 laser (wavelength 10.6 μm, power 30 W) was used to punch holes in the medical PET film, with a pore size of 20 μm and a pore density of 300 holes / cm 2 After completion, spray 50nm fluorosilane hydrophobic coating.

[0084] 2) Raw material processing in temperature control layer

[0085] Paraffin wax was melted to 60°C and vacuum impregnated (-0.1 MPa) into the pores of mesoporous silica. Magnesium stearate was added and mixed, and then pressed into 0.5 mm sheets using a double-roll calender (50°C, 5 MPa).

[0086] 3) Preparation of drug-layered microcapsules

[0087] The wormwood essential oil was mixed with molten paraffin and injected into 2.5% sodium alginate solution, cross-linked with 2% CaCl2 for 30 minutes, vacuum dried at 45°C, and sieved into 80-120 μm microcapsules (drug loading capacity 8 mg / cm 2 ).

[0088] 4) Preparation of adhesive layer

[0089] Silicone adhesive and hydrogenated castor oil were mixed in a vacuum mixer (-0.08 MPa, 200 rpm) for 30 minutes, coated on a PET release film, and then thermally cured at 80°C for 20 minutes.

[0090] 2. Interlayer composite and assembly

[0091] S1, pre-combination of the temperature control layer and the drug layer: align the temperature control layer and the drug layer, press them together in a hot press (60°C, 0.3 MPa) for 30 seconds to eliminate interface bubbles.

[0092] S2, surface lamination: Apply 10 μm medical-grade UV adhesive (365 nm light source, 10 mW / cm2) on the upper surface of the temperature control layer, cover it with laser-perforated PET film, and then cure it for 30 seconds.

[0093] S3, adhesive layer lamination: remove the release film, laminate the adhesive layer to the bottom of the drug layer, and use a roller press (0.1 MPa, 5 m / min) to remove bubbles.

[0094] 3. Finished product molding and packaging

[0095] S4. Die-cutting: Use a circular die-cutting machine to cut into a standard size of 10cm×14cm, with edge chamfer R=1mm, and simultaneously detect the thickness tolerance (±5μm).

[0096] Quality Inspection and Packaging: Infrared thermal imaging is used to inspect the uniformity of the temperature control layer, gas chromatography is used to spot-check the drug loading of microcapsules, and qualified products are automatically packaged. Fully automated processes: From raw material feeding to finished product packaging, integrated modules such as laser drilling, vacuum impregnation, and microcapsule granulation reduce manual intervention. Closed-loop control of process parameters: Real-time monitoring of temperature (±1°C), pressure (±0.05MPa), and thickness (±5μm) ensures batch consistency.

[0097] Example 1:

[0098] According to the preparation method of the above-mentioned smart temperature control patch, a health care patch was prepared according to the following parameters:

[0099] Temperature control layer: paraffin wax / mesoporous silica composite sheet, melted at 60°C, impregnated at -0.1MPa, and rolled at 50°C / 5MPa;

[0100] Drug layer: 80-120μm microcapsules, drug loading 8mg / cm 2 ;

[0101] Interlayer compounding: 60℃ / 0.3MPa / 30 seconds.

[0102] Comparative Example 1 (no phase change material temperature control layer):

[0103] According to the preparation method of the above-mentioned smart temperature control patch, a health care patch was prepared according to the following parameters:

[0104] Temperature control layer: only pure paraffin sheets (no mesoporous silica, not vacuum impregnated) are used;

[0105] Drug layer: same as Example 1;

[0106] Interlayer compounding: same as in Example 1.

[0107] Example 2:

[0108] According to the preparation method of the above-mentioned smart temperature control patch, a health care patch was prepared according to the following parameters:

[0109] Surface: 20μm pore size / 300 pores / cm 2 , 50nm fluorosilane coating;

[0110] Adhesive layer: -0.08MPa vacuum stirring, 80℃ curing;

[0111] Lamination process: UV curing (10μm adhesive layer) and roller pressing (0.1MPa / 5m / min).

[0112] Comparative Example 2 (no hydrophobic coating / conventional adhesive layer):

[0113] According to the preparation method of the above-mentioned smart temperature control patch, a health care patch was prepared according to the following parameters:

[0114] Surface: Only laser punched, no fluorosilane coating sprayed;

[0115] Adhesive layer: conventional pressure-sensitive adhesive (without hydrogenated castor oil added);

[0116] Lamination process: same as Example 2.

[0117] Example 3:

[0118] According to the preparation method of the above-mentioned smart temperature control patch, a health care patch was prepared according to the following parameters:

[0119] Drug layer: 2.5% sodium alginate + 2% CaCl2 cross-linked, vacuum dried at 45°C;

[0120] Process control: Screening of 80-120 μm microcapsules (accounting for ≥85%).

[0121] Comparative Example 3 (traditional microcapsule process):

[0122] According to the preparation method of the above-mentioned smart temperature control patch, a health care patch was prepared according to the following parameters:

[0123] Drug layer: only molten paraffin was used to coat the mugwort essential oil (no sodium alginate cross-linking was used);

[0124] Process control: natural drying, unscreened particle size.

[0125] 2. Performance Testing

[0126] 1. Precision temperature control test

[0127] Test objective: To verify the ability of temperature fluctuation to dynamically regulate drug release rate.

[0128] Temperature stability test

[0129] Test method: Attach the health patch to the constant temperature simulated skin (37℃) and use an infrared thermal imager to monitor the temperature changes within 8 hours.

[0130] Reference standard: GB / T 20284-2006 (Test for thermal stability of phase change materials).

[0131] 2. Air permeability-adhesion performance balance test

[0132] Test objective: To verify the optimization effect of microporous structure and hydrophobic coating on air permeability and adhesive strength.

[0133] Air permeability test

[0134] Test method: Use an air permeability tester (water vapor transmission method), cover the surface layer of the health patch (laser-perforated PET film) on a test cup, and test at a temperature of 37°C and a humidity of 90% for 24 hours.

[0135] Reference standard: GB / T 12704-2008 (Test method for air permeability of fabrics).

[0136] Adhesion performance test

[0137] Test method: Peel force test: stick the adhesive layer of the health patch to a stainless steel plate, peel it off at an angle of 180° using a universal material testing machine, and record the maximum peel force (N / cm).

[0138] 3. Drug Delivery Efficiency Breakthrough Test

[0139] Test objective: To verify the effect of sodium alginate cross-linking process on improving drug loading and stability.

[0140] Drug loading determination

[0141] Test method: Accurately weigh the drug-layer microcapsules (about 0.1 g), dissolve them in ethanol, and then quantitatively analyze the wormwood essential oil content by HPLC.

[0142] Volatile loss rate test

[0143] Test method: Place the microcapsules in a 40℃ accelerated aging chamber for 48 hours, weigh them and calculate the volatility loss rate.

[0144] (2) Test results:

[0145] Table 1: Test results of precise temperature control

[0146]

[0147] Table 2: Test results of air permeability and adhesion performance

[0148]

[0149] Table 3: Test results of microcapsule drug loading efficiency

[0150]

[0151] As can be seen from Table 2, the temperature fluctuation range (8 hours) of the health patch prepared in Example 1 of the present invention was only ±1.4°C, which is excellent. In contrast, in Comparative Example 1, which used only pure paraffin sheets (no mesoporous silica, no vacuum impregnation), the temperature fluctuation range (8 hours) was ±5.6°C. Furthermore, the 48-hour drug volatility loss rate of Example 3 was only 3.2%, while the 48-hour drug volatility loss rate of Comparative Example 3, which used only molten paraffin to coat the wormwood essential oil (without sodium alginate cross-linking), was 43.5%, which was unexpected before the experiment.

[0152] The above-described embodiments merely illustrate several implementations of the present invention. While the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that a person skilled in the art would be able to make numerous variations and improvements without departing from the spirit of the present invention, and all such variations and improvements fall within the scope of protection of the present invention.

Claims

1. Intelligent temperature control health care patch, characterized by: include: A surface layer, wherein the surface layer is prepared by punching holes in a medical PET film using a CO2 laser; A temperature control layer attached to the surface layer, the temperature control layer is a phase change energy storage material composite system, the phase change energy storage material composite system is prepared by melting paraffin to 60°C, vacuum impregnating it into the pores of mesoporous silica under -0.1 MPa conditions, adding magnesium stearate and mixing evenly, and hot pressing at 50°C and 5 MPa conditions to form a sheet with a thickness of 0.5 mm; A drug layer is attached to the surface of the temperature control layer, wherein the drug layer is prepared by mixing wormwood essential oil with molten paraffin, injecting it into a 2.5% sodium alginate solution, cross-linking it with 2% CaCl2 for 30 minutes, vacuum drying it at 45°C, and sieving 80-120 μm microcapsules; and an adhesive layer adhered to the surface of the drug layer, wherein the adhesive layer is prepared by stirring silicone glue and hydrogenated castor oil in a blender for 30 minutes, coating the mixture on a PET release film, and curing the mixture at 80° C. for 20 minutes.

2. The smart temperature control health care patch according to claim 1, wherein: The wavelength of the CO2 laser is 10.6 μm, the power is 30 W, the diameter of the holes punched on the medical PET film is 20 μm, and the hole density is 300 holes / cm 2 .

3. The intelligent temperature control health care patch according to claim 1, wherein: The surface layer is sprayed with a fluorosilane coating, the thickness of the fluorosilane coating is 50 nm, and the contact angle is ≥110°.

4. The intelligent temperature control health care patch according to claim 1, wherein: The drug loading capacity of the microcapsule is 8 mg / cm 2 .

5. The intelligent temperature-control health-care patch according to claim 1, wherein the stirring conditions in the stirrer are: vacuum degree -0.08 MPa, and rotation speed 200 rpm.

6. The method for preparing the intelligent temperature-control health-care patch according to any one of claims 1 to 5, characterized in that: The following steps are involved: S1, pre-combining the temperature control layer and the drug layer: aligning the temperature control layer and the drug layer and then hot pressing to ensure that there are no bubbles in the temperature control layer and the drug layer; S2, surface lamination: apply medical-grade UV adhesive on the upper surface of the temperature control layer, cover with PET film, and UV cure; S3, adhesive layer lamination: remove the silicone release film, place the adhesive surface on the bottom of the drug layer, and roll to remove air bubbles; S4, die-cutting: Use a circular die-cutting machine to cut into a standard size of 10 cm × 14 cm, with edge chamfer R = 1 mm.

7. The method according to claim 6, wherein: In S1, the hot pressing conditions are: hot pressing at 60° C. and 0.3 MPa for 30 seconds.

8. The method according to claim 6, wherein: In S2, the thickness of the UV glue is 10 μm, the thickness of the UV curing is 365 nm, and the density is 10 mW / cm 2 , time is 30 seconds.

9. The method according to claim 6, wherein: In S3, the roller pressing pressure was 0.1 MPa and the speed was 5 m / min.

Images